Other antibody specificities, such as anti-annexin A5 and anti-vimentin antibodies, might be considered for thrombotic risk assessment only in selected patients, particularly when other aPL tests are negative and in the presence of clinical signs and/or symptoms strongly suggestive for APS (26, 30). The gene discussed is VIM; the disease is autoimmune polyendocrinopathy.